Bladder Cancer, Version 2.2016 Featured Updates to the NCCN Guidelines

Peter E. Clark, Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Jason A. Efstathiou, Thomas W. Flaig, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Noah Hahn, Harry W. Herr, Christopher Hoimes, Brant A. Inman, A. Karim Kader, Adam S. Kibel, Timothy M. Kuzel, Subodh M Lele, Joshua J. MeeksJeff Michalski, Jeffrey S. Montgomery, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Daniel Petrylak, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Wade J. Sexton, Arlene O. Siefker-Radtke, Guru Sonpavde, Jonathan Tward, Geoffrey Wile, Mary A. Dwyer, Courtney Smith

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

These NCCN Guidelines Insights discuss the major recent updates to the NCCN Guidelines for Bladder Cancer based on the review of the evidence in conjunction with the expert opinion of the panel. Recent updates include (1) refining the recommendation of intravesical bacillus Calmette-Guérin, (2) strengthening the recommendations for perioperative systemic chemotherapy, and (3) incorporating immunotherapy into second-line therapy for locally advanced or metastatic disease. These NCCN Guidelines Insights further discuss factors that affect integration of these recommendations into clinical practice.

Original languageEnglish (US)
Pages (from-to)1213-1224
Number of pages12
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume14
Issue number10
StatePublished - Oct 1 2016

Fingerprint

Urinary Bladder Neoplasms
Guidelines
Expert Testimony
Immunotherapy
Bacillus
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Clark, P. E., Spiess, P. E., Agarwal, N., Bangs, R., Boorjian, S. A., Buyyounouski, M. K., ... Smith, C. (2016). Bladder Cancer, Version 2.2016 Featured Updates to the NCCN Guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 14(10), 1213-1224.

Bladder Cancer, Version 2.2016 Featured Updates to the NCCN Guidelines. / Clark, Peter E.; Spiess, Philippe E.; Agarwal, Neeraj; Bangs, Rick; Boorjian, Stephen A.; Buyyounouski, Mark K.; Efstathiou, Jason A.; Flaig, Thomas W.; Friedlander, Terence; Greenberg, Richard E.; Guru, Khurshid A.; Hahn, Noah; Herr, Harry W.; Hoimes, Christopher; Inman, Brant A.; Kader, A. Karim; Kibel, Adam S.; Kuzel, Timothy M.; Lele, Subodh M; Meeks, Joshua J.; Michalski, Jeff; Montgomery, Jeffrey S.; Pagliaro, Lance C.; Pal, Sumanta K.; Patterson, Anthony; Petrylak, Daniel; Plimack, Elizabeth R.; Pohar, Kamal S.; Porter, Michael P.; Sexton, Wade J.; Siefker-Radtke, Arlene O.; Sonpavde, Guru; Tward, Jonathan; Wile, Geoffrey; Dwyer, Mary A.; Smith, Courtney.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 14, No. 10, 01.10.2016, p. 1213-1224.

Research output: Contribution to journalArticle

Clark, PE, Spiess, PE, Agarwal, N, Bangs, R, Boorjian, SA, Buyyounouski, MK, Efstathiou, JA, Flaig, TW, Friedlander, T, Greenberg, RE, Guru, KA, Hahn, N, Herr, HW, Hoimes, C, Inman, BA, Kader, AK, Kibel, AS, Kuzel, TM, Lele, SM, Meeks, JJ, Michalski, J, Montgomery, JS, Pagliaro, LC, Pal, SK, Patterson, A, Petrylak, D, Plimack, ER, Pohar, KS, Porter, MP, Sexton, WJ, Siefker-Radtke, AO, Sonpavde, G, Tward, J, Wile, G, Dwyer, MA & Smith, C 2016, 'Bladder Cancer, Version 2.2016 Featured Updates to the NCCN Guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 14, no. 10, pp. 1213-1224.
Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK et al. Bladder Cancer, Version 2.2016 Featured Updates to the NCCN Guidelines. JNCCN Journal of the National Comprehensive Cancer Network. 2016 Oct 1;14(10):1213-1224.
Clark, Peter E. ; Spiess, Philippe E. ; Agarwal, Neeraj ; Bangs, Rick ; Boorjian, Stephen A. ; Buyyounouski, Mark K. ; Efstathiou, Jason A. ; Flaig, Thomas W. ; Friedlander, Terence ; Greenberg, Richard E. ; Guru, Khurshid A. ; Hahn, Noah ; Herr, Harry W. ; Hoimes, Christopher ; Inman, Brant A. ; Kader, A. Karim ; Kibel, Adam S. ; Kuzel, Timothy M. ; Lele, Subodh M ; Meeks, Joshua J. ; Michalski, Jeff ; Montgomery, Jeffrey S. ; Pagliaro, Lance C. ; Pal, Sumanta K. ; Patterson, Anthony ; Petrylak, Daniel ; Plimack, Elizabeth R. ; Pohar, Kamal S. ; Porter, Michael P. ; Sexton, Wade J. ; Siefker-Radtke, Arlene O. ; Sonpavde, Guru ; Tward, Jonathan ; Wile, Geoffrey ; Dwyer, Mary A. ; Smith, Courtney. / Bladder Cancer, Version 2.2016 Featured Updates to the NCCN Guidelines. In: JNCCN Journal of the National Comprehensive Cancer Network. 2016 ; Vol. 14, No. 10. pp. 1213-1224.
@article{35ef94a431624644bf7e6d99919eed16,
title = "Bladder Cancer, Version 2.2016 Featured Updates to the NCCN Guidelines",
abstract = "These NCCN Guidelines Insights discuss the major recent updates to the NCCN Guidelines for Bladder Cancer based on the review of the evidence in conjunction with the expert opinion of the panel. Recent updates include (1) refining the recommendation of intravesical bacillus Calmette-Gu{\'e}rin, (2) strengthening the recommendations for perioperative systemic chemotherapy, and (3) incorporating immunotherapy into second-line therapy for locally advanced or metastatic disease. These NCCN Guidelines Insights further discuss factors that affect integration of these recommendations into clinical practice.",
author = "Clark, {Peter E.} and Spiess, {Philippe E.} and Neeraj Agarwal and Rick Bangs and Boorjian, {Stephen A.} and Buyyounouski, {Mark K.} and Efstathiou, {Jason A.} and Flaig, {Thomas W.} and Terence Friedlander and Greenberg, {Richard E.} and Guru, {Khurshid A.} and Noah Hahn and Herr, {Harry W.} and Christopher Hoimes and Inman, {Brant A.} and Kader, {A. Karim} and Kibel, {Adam S.} and Kuzel, {Timothy M.} and Lele, {Subodh M} and Meeks, {Joshua J.} and Jeff Michalski and Montgomery, {Jeffrey S.} and Pagliaro, {Lance C.} and Pal, {Sumanta K.} and Anthony Patterson and Daniel Petrylak and Plimack, {Elizabeth R.} and Pohar, {Kamal S.} and Porter, {Michael P.} and Sexton, {Wade J.} and Siefker-Radtke, {Arlene O.} and Guru Sonpavde and Jonathan Tward and Geoffrey Wile and Dwyer, {Mary A.} and Courtney Smith",
year = "2016",
month = "10",
day = "1",
language = "English (US)",
volume = "14",
pages = "1213--1224",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "10",

}

TY - JOUR

T1 - Bladder Cancer, Version 2.2016 Featured Updates to the NCCN Guidelines

AU - Clark, Peter E.

AU - Spiess, Philippe E.

AU - Agarwal, Neeraj

AU - Bangs, Rick

AU - Boorjian, Stephen A.

AU - Buyyounouski, Mark K.

AU - Efstathiou, Jason A.

AU - Flaig, Thomas W.

AU - Friedlander, Terence

AU - Greenberg, Richard E.

AU - Guru, Khurshid A.

AU - Hahn, Noah

AU - Herr, Harry W.

AU - Hoimes, Christopher

AU - Inman, Brant A.

AU - Kader, A. Karim

AU - Kibel, Adam S.

AU - Kuzel, Timothy M.

AU - Lele, Subodh M

AU - Meeks, Joshua J.

AU - Michalski, Jeff

AU - Montgomery, Jeffrey S.

AU - Pagliaro, Lance C.

AU - Pal, Sumanta K.

AU - Patterson, Anthony

AU - Petrylak, Daniel

AU - Plimack, Elizabeth R.

AU - Pohar, Kamal S.

AU - Porter, Michael P.

AU - Sexton, Wade J.

AU - Siefker-Radtke, Arlene O.

AU - Sonpavde, Guru

AU - Tward, Jonathan

AU - Wile, Geoffrey

AU - Dwyer, Mary A.

AU - Smith, Courtney

PY - 2016/10/1

Y1 - 2016/10/1

N2 - These NCCN Guidelines Insights discuss the major recent updates to the NCCN Guidelines for Bladder Cancer based on the review of the evidence in conjunction with the expert opinion of the panel. Recent updates include (1) refining the recommendation of intravesical bacillus Calmette-Guérin, (2) strengthening the recommendations for perioperative systemic chemotherapy, and (3) incorporating immunotherapy into second-line therapy for locally advanced or metastatic disease. These NCCN Guidelines Insights further discuss factors that affect integration of these recommendations into clinical practice.

AB - These NCCN Guidelines Insights discuss the major recent updates to the NCCN Guidelines for Bladder Cancer based on the review of the evidence in conjunction with the expert opinion of the panel. Recent updates include (1) refining the recommendation of intravesical bacillus Calmette-Guérin, (2) strengthening the recommendations for perioperative systemic chemotherapy, and (3) incorporating immunotherapy into second-line therapy for locally advanced or metastatic disease. These NCCN Guidelines Insights further discuss factors that affect integration of these recommendations into clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=84990174465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990174465&partnerID=8YFLogxK

M3 - Article

C2 - 27697976

AN - SCOPUS:84990174465

VL - 14

SP - 1213

EP - 1224

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 10

ER -